.2003 .. Global Tuberculosis Report, 03 : 1776.
Aithal GP,Watkins PB,Andrade RJ,Larrey D,Molokhia M,Takikawa H .2011 .Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 10(6) : 806-15.
Wang T,Lin S,Shie S,Chou P,Huang C,Chung F. Clinical C,High-Concentration Isoniazid- Monoresistant Tuberculosis C .2014 .Characteristics and Treatment Outcomes of Patients with Low-. , 10(1) : 1-6.
Bao Y,Ma X,Rasmussen TP,Zhong XB .2018 .Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury. Curr Pharmacol Rep, 10(3) : 171-81.
Gurumurthy P,Ramachandran G,Kumar AKH,Rajasekaran S,Padmapriyadarsini C,Swaminathan S .2004 .Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease. Society, 10(11) : 4473-5.
Chigutsa E,Visser ME,Swart EC,Denti P,Pushpakom S,Egan D .2011 .The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications. Antimicrob Agents Chemother, 10(9) : 10-7.
Gumbo T,Louie A,Deziel MR,Liu W,Parsons LM,Salfinger M .2007 .Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother, 10(11) : 06-8.
Jindani A,Harrison TS,Nunn AJ,Phillips PPJ,Churchyard GJ,Charalambous S .2014 .High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med, 10 : 1599-608.
Ruslami R,Menzies D .2017 .Finding the right dose of rifampicin, and the right dose of optimism. Lancet Infect Dis, 3099(16) : 30315-2.
Milstein M,Lecca L,Peloquin C,Mitchison D,Seung K,Pagano M .2016 .Evaluation of high-dose rifampin in patients with new, smearpositive tuberculosis (HIRIF): Study protocol for a randomized controlled trial. BMC Infect Dis, 10(1) : 1-7.
Steingart KR,Jotblad S,Robsky K,Deck D,Hopewell PC,Huang D .2011 .Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review [Review article]. Int J Tuberc Lung Dis, 15(3) : 305-16.
Boeree MJ,Diacon AH,Dawson R,Narunsky K,Du Bois J,Venter A .2015 .A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med, 10(9) : 1264OC-65.
Ruslami R,Nijland HMJ,Alisjahbana B,Parwati I,Van Crevel R,Aarnoutse RE .2007 .Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother, 10(7) : 06-51.
Boeree MJ,Van Balen GP,Aarnoutse RA .2011 .High-dose rifampicin: How do we proceed?. Int J Tuberc Lung Dis, 10(8) : 1133.
Hu Y,Liu A,Ortega-Muro F,Alameda-Martin L,Mitchison D,Coates A .2015 .High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol, 10 : 1-10.
Boeree MJ,Heinrich N,Aarnoutse R,Diacon AH,Dawson R,Rehal S .2017 .High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis, 3099(16) : 30274-2.
Onorato L,Gentile V,Russo A,Caprio G Di,Alessio L,Chiodini P .2021 .Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis : a systematic review and meta-analysis. Clin Microbiol Infect, 27(6) : 830-7.
.2009 .Treatment of Tuberculosis Guidelines. , : .
.2014 .National Institute of Allergy and Infectious Diseases. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. , 10 : 0003.
. .. Global Tuberculosis Report 2016. Geneva: 2016. doi:ISBN 978 92 4 156539 4, : .
Petros Z,Kishikawa J,Makonnen E,Yimer G,Habtewold A,Aklillu E .2017 .57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians. Front Pharmacol, 10 : 1-9.
Walker L,Yip V,Pirmohamed M. .2014 .Adverse Drug Reactions. -12-386882-4, 10 : 00020-7.
Hassen Ali A,Belachew T,Yami A,Ayen WY .2013 .Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients. Ethiopia: Nested Case-Control Study. PLoS One, 10(5) : .
Björnsson ES .2016 .Hepatotoxicity by drugs: The most common implicated agents. Int J Mol Sci, 10(2) : 224.
Sarges P,Steinberg JM,Lewis JH .2016 .Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. , 10(9) : 801-21.
Björnsson ES .2015 .Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol, 10(3) : 327-34.
Wang P,Pradhan K,Zhong XB,Ma X .2016 .Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B, 07(5) : 384-92.
Metushi I,Uetrecht J,Phillips E .2016 .Mechanism of isoniazid-induced hepatotoxicity: Then and now. Br J Clin Pharmacol, 10(6) : 1030-6.
Daly AK .2018 .Pharmacogenetics of Adverse Drug Reactions. Pharmacogenetics Individ. Ther. First Edit, 03 : 295-321.
Kim SH,Kim SH,Lee JH,Lee BH,Kim YS,Park JS .2011 .Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs. Tuberculosis, 09(1) : 100-4.
Andrade R,Agundez J,Lucena M,Martinez C,Cueto R,Garcia-Martin E. .2009 .Pharmacogenomics in Drug Induced Liver Injury. Curr Drug Metab, 10(9) : 956-70.
Yew WW,Chang KC,Chan DP. Oxidative,Stress DP. Oxidative,First-Line Antituberculosis DP. Oxidative,Hepatotoxicity DP. Oxidative .2018 .. Antimicrob Agents Chemother, 62(8) : 1-11.
Oscanoa T,Moscol S,Amado J. .2020 .Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in lima, peru. Rev Peru Med Exp Salud Publica, 37(3) : 516-20.
Kwon BS,Kim Y,Lee SH,Lim SY,Lee YJ,Park JS .2020 .The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One, 15(7 July)) : 1-10.
Waggiallah HA,Eltayeb LB,BinShaya AS,Elmahi OM,Techol J Biochem .2020 .A saga of Hepcidin anti-microbial Effectiveness as Iron Acquisitor and Anemia Initiator in Mycobacterium Tuberculosis Infection. , 11(2) : 128-34.